.jpg "Inogen (NASDAQ: INGN)")
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Inogen (NASDAQ: INGN), Radius Health (NASDAQ: RDUS) and Ampliphi Biosciences (AMEX: APHB) with bullish sentiments.
Inogen (NASDAQ: INGN)
In a report issued on June 11, Michael Matson from Needham reiterated a Buy rating on Inogen (NASDAQ: INGN), with a price target of $215. The company’s shares opened today at $185, close to its 52-week high of $193.14.
Matson observed:
“We hosted for management meetings in Boston and Toronto last week. Recent sales and marketing investments (CRM, training, and new hires) are paying off with higher growth. We think INGN’s DTC channel is a competitive advantage and one that is difficult for competitors to copy. INGN is increasingly spending its R&D dollars on research as opposed to development; we expect it to launch the G5 next year. The US POC market remains significantly underpenetrated and international markets, particularly emerging markets, have minimal penetration. Despite facing some much larger competitors, we believe INGN has the best POCs and that it can maintain its lead. We expect INGN to sustain very strong revenue growth for the next few years and to continue to deliver upside to consensus estimates and we reiterate our Strong Buy rating.”
According to TipRanks.com, Matson is a 5-star analyst with an average return of 10.7% and a 63.3% success rate. Matson covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Cardiovascular Systems, and Zimmer Biomet Holdings.
Currently, the analyst consensus on Inogen is Strong Buy and the average price target is $195, representing a 5.4% upside.
In a report issued on May 30, Piper Jaffray also maintained a Buy rating on the stock with a $190 price target.
See today’s analyst top recommended stocks >>
Radius Health (NASDAQ: RDUS)
In a report issued on June 11, Mara Goldstein from Cantor Fitzgerald maintained a Buy rating on Radius Health (NASDAQ: RDUS), with a price target of $58. The company’s shares opened today at $29.89.
Goldstein observed:
“. We maintain an Overweight rating and our 12-month price target of $58 on RDUS shares. The company is in the midst of TYMLOS commercialization and marketing efforts. We think this market will evolve, and we also see opportunity in elacestrant, which is set to enter a Phase III program for the treatment of hormonally sensitive breast cancer. Although the shares have struggled, we still like the assets and maintain an Overweight rating on the shares.”
According to TipRanks.com, Goldstein is a 2-star analyst with an average return of 0.4% and a 40.4% success rate. Goldstein covers the Healthcare sector, focusing on stocks such as Karyopharm Therapeutics, CytomX Therapeutics Inc, and Genocea Biosciences.
Radius Health has an analyst consensus of Strong Buy, with a price target consensus of $56.67.
Ampliphi Biosciences (AMEX: APHB)
In a report issued on June 11, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Ampliphi Biosciences (AMEX: APHB), with a price target of $6. The company’s shares opened today at $1.29.
Pantginis noted:
“We anticipate additional case studies to be presented at medical conferences during 2018 as well.”
According to TipRanks.com, Pantginis ‘ ranking currently consits of no stars on a 0-5 ranking scale, with an average return of -9.4% and a 36.1% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, Applied Genetic Technologies, and Iovance Biotherapeutics Inc.
Ampliphi Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $6.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
